Navigation Links
Stored Ovarian Tissue Needs Testing Before Re-Implantation
Date:4/24/2008

Inadequate safeguards could mean a return of cancer, study warns

THURSDAY, April 24 (HealthDay News) -- Cancer can return in patients who have been successfully treated if ovarian or testicular tissue they had stored in hope of regaining fertility is transplanted back into their bodies without it being adequately checked for cancer cells, according to a new report.

Researchers at two university hospitals in Israel, writing in the April 22 issue of Human Reproduction, then warned that most fertility centers lack the skills and technology to ensure the tissue is free of residual cancer cells.

Hundreds of cancer patients worldwide have ovarian tissue and testicular tissue frozen in the hope of being able to have children once their treatment has finished. However, it is possible for the original cancer to re-infect the body when the tissue is re-implanted.

"We think it's vitally important to raise awareness amongst cancer patients, fertility specialists, oncologists and hematologists. There are few fertility centers in the world with the expertise and the technology to run the types of tests on tissue that are needed to detect residual cancer," first author Dror Meirow, who leads the fertility preservation program at Chaim Sheba Medical Center, said in a prepared statement.

Over 10 years, Meirow and his team collected and froze several strips of tissue from 56 women about to receive chemotherapy for hematological cancers such as Hodgkin lymphoma, non-Hodgkin lymphoma and leukemia. Over the years, the strips were thawed and checked for cancer cells using the most modern methods available at the time. The results were compared with the same tests carried out on the patients' diseased tissue at the time of harvest to ensure the tests were capable of detecting cancer when it was known to be present.

Only one test ever detected minimal residual disease in ovarian tissue: modern, highly sensitive, real-time polymerase chain reaction (PCR), a test that amplifies sections of DNA to detect molecular markers that would indicate the presence of cancer cells. The authors suggested that, as methods for detecting cancer cells are improving all the time, and ovarian tissue can be stored for more than 10 years, tests to detect residual disease should be carried out just before transplantation rather than at the time of collection. To do this, it is necessary to freeze smaller pieces of ovarian tissue separately for minimal residual disease investigation.

"The next step is to inform patients about the increasing success of ovarian tissue transplantation, to continue to improve the success of ovarian tissue transplantation, but also to call on fertility centers that store ovarian tissue to look for minimal residual disease and to start freezing tissue now for future investigation," Meirow said. "All of this holds true for testicular tissue, too, although we are not so advanced in successfully removing, storing and transplanting testicular tissue as we are with ovarian tissue."

More information

The American Cancer Society has more about ovarian cancer treatment.



-- Kevin McKeever



SOURCE: European Society for Human Reproduction and Embryology, news release, April 21, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Cancer could return unless stored ovarian tissue undergoes adequate testing before re-implantation
2. Former Actor has Mobility Restored With Power Wheelchair Gift From The Scooter Store
3. Lymphatic vessel and lymph node function are restored with growth factor treatment
4. 600 Smiles Restored Thanks to the AACDCFs Give Back A Smile Program - October Marks National Domestic Violence Awareness Month
5. Scientists Develop Natural Protection for Stored Foods
6. Drug compound leads to death of ovarian cancer cells resistant to chemotherapy
7. FASgen Diagnostic Tests Identify Ovarian Cancer Progression and Apoptosis
8. Specialized Care for Ovarian Cancer Improves Outcomes
9. Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers
10. Advanced-stage ovarian cancer patients with BRCA live longer, may respond better to treatment
11. Gleevec May Disrupt Ovarian Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: